Tweet
Zacks Investment Research upgraded shares of CONSORT Med PLC/S (OTCMKTS:CSRMY) from a strong sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, "Consort Medical Plc engages in the design, development, manufacture and sale of medical drug delivery devices. It operates through the Bespak and Aesica segments. Bespak segment develops and produces drug delivery devices which serves pharmaceutical companies with inhaler and auto-injector technologies. Aesica segment is a contract development and manufacturing organization which serves pharmaceutical firms with active pharmaceutical ingredient and finished dose formulation development and manufacturing services. Consort Medical Plc is headquartered in Hemel Hempstead, United Kingdom. " Get CONSORT Med PLC/S alerts:
CSRMY opened at $14.39 on Tuesday. CONSORT Med PLC/S has a 52 week low of $13.00 and a 52 week high of $16.65. The stock has a market cap of $709.21 million, a price-to-earnings ratio of 17.34 and a beta of 0.01. The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, November 5th. Shareholders of record on Friday, September 28th will be issued a dividend of $0.159 per share. The ex-dividend date is Thursday, September 27th. CONSORT Med PLC/S's dividend payout ratio (DPR) is presently 28.92%.
About CONSORT Med PLC/S
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
Get a free copy of the Zacks research report on CONSORT Med PLC/S (CSRMY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News &Ratings for CONSORT Med PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONSORT Med PLC/S and related companies with MarketBeat.com's FREE daily email newsletter 